Is Emergent Biosolutions Inc (NYSE: EBS) A Stock A New Investor Should Consider Now?

Emergent Biosolutions Inc (NYSE:EBS) shares, rose in value, with the stock price up by 4.63% to the previous day’s close as strong demand from buyers drove the stock to $2.26.

Actively observing the price movement in the last trading, the stock closed the session at $2.16. The value of beta (5-year monthly) was 1.22. Referring to stock’s 52-week performance, its high was $13.67, and the low was $1.42. On the whole, EBS has fluctuated by -28.71% over the past month.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


With the market capitalization of Emergent Biosolutions Inc currently standing at about $117.97 million, investors are eagerly awaiting this quarter’s results, scheduled for May 07, 2024 – May 13, 2024. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.83, which is expected to increase to -$0.63 for fiscal year -$2 and then to about $3.67 by fiscal year 2025. Data indicates that the EPS growth is expected to be 67.90% in 2025, while the next year’s EPS growth is forecast to be 283.50%.

Analysts have estimated the company’s revenue for the quarter at $224.5 million, with a low estimate of $224.5 million and a high estimate of $224.5 million. Wall Street analysts also predicted that in 2025, the company’s y-o-y revenues would reach $1.02 billion, representing a decrease of -2.30% from the revenues reported in the last year’s results.

Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that EBS’s technical picture suggests that short-term indicators denote the stock is a Hold on average. However, medium term indicators have put the stock in the category of 50% Sell while long term indicators on average have been pointing out that it is a 50% Sell.

The stock’s technical analysis shows that the PEG ratio is about 0, with the price of EBS currently trading nearly -11.68% and -1.12% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 44.38, while the 7-day volatility ratio is showing 10.49% which for the 30-day chart, stands at 10.62%. Furthermore, Emergent Biosolutions Inc (EBS)’s beta value is 1.20, and its average true range (ATR) is 0.27.

A comparison of Emergent Biosolutions Inc (EBS) with its peers suggests the former has fared considerably weaker in the market. EBS showed an intraday change of 4.63% in last session, and over the past year, it shrunk by -78.19%%.

Data on historical trading for Emergent Biosolutions Inc (NYSE:EBS) indicates that the trading volumes over the past 10 days have averaged 1.13 million and over the past 3 months, they’ve averaged 3.10 million. According to company’s latest data on outstanding shares, there are 52.20 million shares outstanding.

Nearly 4.08% of Emergent Biosolutions Inc’s shares belong to company insiders and institutional investors own 78.65% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 4.91 million shares as on Mar 15, 2024, resulting in a short ratio of 0.74. According to the data, the short interest in Emergent Biosolutions Inc (EBS) stood at 9.41% of shares outstanding as of Mar 15, 2024; the number of short shares registered in Feb 15, 2024 reached 11.54 million. The stock has fallen by -5.83% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the EBS stock heading into the next quarter.